The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Narendranath EpperlaDuring the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, the Lymphoma Hub was pleased to speak with Narendranath Epperla, Ohio State University, Columbus, US. We asked, How robust is POD24 (progression of disease within 24 months) as a predictor of survival in indolent lymphomas?
How robust is POD24 as a predictor of survival in indolent lymphomas?
Epperla begins by discussing the prognostic relevance of POD24, specifically in a multicenter U.S. based cohort study of patients with marginal zone lymphoma. He concludes that patients with POD24 had poorer outcomes compared with non-POD24 patients, outlining POD24 as an important clinical predictor of high-risk patients with follicular lymphoma or marginal zone lymphoma.